Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerenis Therapeutics, a France-based pharmaceutical company, has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis based on high-density lipoprotein therapy.
Subscribe to our email newsletter
This technology is based on the findings of a study led by Jean-Claude Tardif at the Montreal Heart Institute research center in Canada.
In Dr Tardif’s placebo-controlled study in rabbit aortic valve stenosis (AVS) models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification, the company said.
Jean-Louis Dasseux, president and CEO of Cerenis, said: We are very pleased to add this exciting new intellectual property to our growing portfolio of high-density lipoprotein therapies. Currently, patients who suffer from severe AVS have no option other than surgical valve replacement. Even after newer, minimally invasive surgery, there are risks of valve wear and blood clots, requiring permanent treatment with blood thinners.
Cerenis is grateful to Dr Tardif and his team for their work, and we look forward to moving this very promising treatment approach for AVS into clinical development.